Pharma gets no respect from the public. But instead of complaining about it, industry should stop whining and start leading. Here's a seven-point starter kit.
Mar 1, 2007
By:
Pam Maraldo and, Eric Lister, MD
We all know that pharma is facing hard times: cut-throat competition, regulatory constraints, patent expirations, rusty pipelines, rising generics, falling revenues—and, perhaps most important, a firestorm of consumer anger over drug prices and safety now being restoked by the new Democratic Congress. Nevertheless, industry persists in "staying the course"—sound familiar?—rather than charting a bold new strategy. Its two top priorities remain opposing government price controls and thwarting patent laws favorable to generics. These defensive tactics are hardly the hallmark of leadership.
|
|
By engaging consumers and taking control of the debate, Industry can salvage its Reputation.
Sep 1, 2002
By:
Eric Lister, MD, Pam Maraldo
On the heels of ABC's Peter Jennings special, "Bitter Medicine," which aired Wednesday, May 29, 2002, one can make a strong case that the pharma industry has a lot of fence mending to do.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
